Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

January 13, 2026 updated by: M.D. Anderson Cancer Center
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objectives To prospectively evaluate graft options and choice of donor by patient ancestry and SES for allograft candidates at MDACC.

Secondary Objectives

  • To prospectively evaluate time to transplant for allograft candidates at MDACC.
  • To evaluate treatment-related mortality for allograft candidates at MDACC.
  • To assess overall survival for allograft candidates at MDACC.
  • To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC.
  • To evaluate receipt of an optimal graft for allograft recipients at MDACC.

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • MD Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • Warren Fingrut, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

MD Anderson Cancer Center

Description

Inclusion Criteria:

  1. ≥ 18 years of age.
  2. Candidate for allogeneic transplantation

Exclusion Criteria:

1) Allogeneic stem cell transplantation not medically indicated.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Prospective evaluation
Participants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record.
Behavioral: Patient Ancestry Questionnaires
Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Patient Ancestry Questionnaire
Time Frame: Through study completion; an average of 1 year.
Through study completion; an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Warren Fingrut, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2024

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2029

Study Registration Dates

First Submitted

May 31, 2024

First Submitted That Met QC Criteria

June 4, 2024

First Posted (Actual)

June 10, 2024

Study Record Updates

Last Update Posted (Estimated)

January 14, 2026

Last Update Submitted That Met QC Criteria

January 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2024-0253
  • NCI-2024-04790 (Other Identifier: NCI-CTRP Clinical Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allogeneic Transplantation

Clinical Trials on Patient Ancestry Questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe